Aytu BioPharma to Present at Lytham Partners' 2026 Investor Conference
Aytu BioPharma, a pharmaceutical company specialising in treatments for central nervous system diseases, will take part in the Lytham Partners Spring 2026 Investor Conference. The event, scheduled for May 28, 2026, will feature a webcast presentation and private meetings with investors. The company’s webcast will begin at 9:15 AM Eastern time on May 28. Viewers can access it live via the conference home page or through a direct link. A replay will also be available afterwards on the Investors section of Aytu BioPharma’s website.
Aytu BioPharma develops medications for complex neurological conditions. Its prescription products include EXXUM (gepirone) extended-release tablets for major depressive disorder and treatments for attention deficit-hyperactivity disorder. The company emphasises patient access programs to ensure optimal treatment outcomes. During the conference, Aytu’s management team will hold virtual one-on-one meetings with interested parties. Investors can arrange these discussions by contacting Lytham Partners.
The conference provides an opportunity for Aytu BioPharma to engage with investors and showcase its pipeline. The webcast and meetings aim to highlight the company’s focus on central nervous system therapies. Further details can be found on the company’s website and LinkedIn page.
